Distribution of CYP2C19 polymorphism and predicted metabolizer phenotypes in the Indian population: A systematic review.
Indian J PharmacolSep 2, 2026 (epub)
Clinical ResearchMedical Genetics
Smriti Singh, Chanchal Goyal, Tejas K Patel et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined the prevalence of CYP2C19 polymorphisms and predicted metabolizer phenotypes in the Indian population. Analyzing data from 31 studies, the research found a pooled prevalence of the CYP2C19*2 allele at 32% (95% CI: 28%-37%), with significant regional variability across India.
Key findings
- CYP2C19*2 allele prevalence was 32% (95% CI: 28%-37%), highest in South India.
- CYP2C19*3 allele prevalence was rare at 1% (95% CI: 0%-1%).
- CYP2C19*17 allele prevalence was 17% (95% CI: 13%-21%), highest in North India.
- Poor metabolizers accounted for 16% (95% CI: 11%-22%) of the population.
Why it matters
Understanding the distribution of CYP2C19 polymorphisms is crucial for personalized medicine, as it influences drug metabolism and efficacy. This knowledge can guide clinicians in optimizing pharmacotherapy for patients in the Indian population.